Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 9/20 | 1.00 |
| ▸ | DRD3 | P35462 | 8/20 | 1.00 |
| ▸ | DRD4 | P21917 | 4/20 | 0.67 |
| ▸ | HTR1D | P28221 | 2/20 | 0.67 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.60 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.60 |
| ▸ | HTR1B | P28222 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 4/20 | 0.57 |
| ▸ | CA2 | P00918 | 4/20 | 0.57 |
| ▸ | ACHE | P22303 | 4/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.57 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2701521 | 1.00 | DRD2 (1.00) | DRD2DRD3DRD4HTR1DMTNR1A | |
| SCHEMBL8394614 | 1.00 | DRD2 (1.00) | DRD2DRD3DRD4HTR1DMTNR1A | |
| Hydrochloric Acid SCHEMBL6339640 | 0.99 | DRD2 (0.97) | DRD2DRD3DRD4HTR1DMTNR1A | |
| SCHEMBL607070 | 0.94 | DRD2 (0.90) | DRD2DRD3DRD4HTR1DMTNR1A | |
| Hydrochloric Acid SCHEMBL11488842 | 0.93 | DRD2 (0.87) | DRD2DRD3DRD4HTR1DMTNR1A | |
| SCHEMBL9757841 | 0.93 | DRD2 (0.86) | DRD2DRD3DRD4HTR1DMTNR1A | |
| SCHEMBL8689197 | 0.88 | DRD2 (0.79) | DRD2DRD3DRD4HTR1DMTNR1A | |
| SCHEMBL6334450 | 0.88 | DRD2 (0.78) | DRD2DRD3DRD4HTR1DMTNR1A | |
| Hydrochloric Acid SCHEMBL11494181 | 0.87 | DRD2 (0.78) | DRD2DRD3DRD4HTR1DMTNR1A | |
| SCHEMBL10395544 | 0.83 | DRD2 (0.71) | DRD2DRD3DRD4HTR1DMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9034877-B2 | Bifunctional/polyfunctional dopamine D2/D3 agonist as neuroprotective agents for treatment of neurodegenerative diseases | WAYNE STATE UNIVERSITY (US) | 2015-05-19 | — | — | US | disclosed |
| US-20120108815-A1 | BIFUNCTIONAL/POLYFUNCTIONAL DOPAMINE D2/D3 AGONIST AS NEUROPROTECTIVE AGENTS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | WAYNE STATE UNIVERSITY (US) | 2012-05-03 | — | — | US | disclosed |
| US-6864266-B2 | 4-piperidinyl alkyl amine derivatives as muscarinic receptor antagonists | SYNTEX (U.S.A.) LLC (US) | 2005-03-08 | — | — | US | disclosed |
| US-20040092554-A1 | 4-piperidinyl alkyl amine derivatives as muscarinic receptor antagonists | BROTHERTON-PLEISS CHRISTINE E (US) | 2004-05-13 | — | — | US | disclosed |
| US-6627644-B2 | Muscarinic receptor antagonists and parasympathetic nervous system. The physiological actions of Acetylcholine are mediated by activation of either nicotinic or muscarinic receptors | SYNTEX (U.S.A.) LLC | 2003-09-30 | — | — | US | disclosed |
| US-20030162780-A1 | 4-PIPERIDINYL ALKYL AMINE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | SYNTEX (U.S.A.) LLC, NAME CHANGED TO ROCHE PALO ALTO LLC | 2003-08-28 | — | — | US | disclosed |
| US-6008219-A | Bicyclic amine derivatives and their use as anti-psychotic agents | SMITHKLINE BEECH P.L.C. (GB) | 1999-12-28 | — | — | US | disclosed |
| WO-1994026703-A1 | NEW CENTRALLY ACTING 5-, 6-, 7-, AND 8-SUBSTITUTED SULPHONE ESTERS OF N-MONOSUBSTITUTED 2-AMINOTETRALINS AND RELATED STRUCTURES | DAMSMA-BLOEM, Anette, J. (NL) | 1994-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162780-A1 | 4-PIPERIDINYL ALKYL AMINE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM1, CHRM3, CHRM2 | DRD2 50/4885DRD3 56/4885DRD4 149/4885 |
| US-20120108815-A1 | BIFUNCTIONAL/POLYFUNCTIONAL DOPAMINE D2/D3 AGONIST AS NEUROPROTECTIVE AGENTS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | DRD3, DRD2, SLC6A3 | DRD2 2/4885DRD3 1/4885DRD4 7/4885 |
| US-20040092554-A1 | 4-piperidinyl alkyl amine derivatives as muscarinic receptor antagonists | CHRM1, CHRM3, CHRM2 | DRD2 50/4885DRD3 56/4885DRD4 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.